Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice
- PMID: 30459211
- PMCID: PMC6258924
- DOI: 10.1182/bloodadvances.2018024851
Absence of functional compensation between coagulation factor VIII and plasminogen in double-knockout mice
Abstract
Plasminogen deficiency is associated with severely compromised fibrinolysis and extravascular deposition of fibrin. In contrast, coagulation factor VIII (FVIII) deficiency leads to prolonged and excessive bleeding. Based on opposing biological functions of plasminogen and FVIII deficiencies, we hypothesized that genetic elimination of FVIII would alleviate the systemic formation of fibrin deposits associated with plasminogen deficiency and, in turn, elimination of plasminogen would limit bleeding symptoms associated with FVIII deficiency. Mice with single and combined deficiencies of FVIII (F8-/-) and plasminogen (Plg-/-) were evaluated for phenotypic characteristics of plasminogen deficiency, including wasting disease, shortened lifespan, rectal prolapse, and multiorgan fibrin deposition. Conversely, to specifically examine the role of plasmin-mediated fibrinolysis on bleeding caused by FVIII deficiency, F8-/- and F8-/-/Plg-/- mice were subjected to a bleeding challenge. Mice with a combined deficiency in FVIII and plasminogen displayed no phenotypic differences relative to mice with single FVIII or plasminogen deficiency. Plg-/- and F8-/-/Plg-/- mice exhibited the same penetrance and severity of wasting disease, rectal prolapse, extravascular fibrin deposits, and reduced viability. Furthermore, following a tail vein-bleeding challenge, no significant differences in bleeding times or total blood loss could be detected between F8-/- and F8-/-/Plg-/- mice. Moreover, F8-/- and F8-/-/Plg-/- mice responded similarly to recombinant FVIII (rFVIII) therapy. In summary, the pathological phenotype of Plg-/- mice developed independently of FVIII-dependent coagulation, and elimination of plasmin-driven fibrinolysis did not play a significant role in a nonmucosal bleeding model in hemophilia A mice.
© 2018 by The American Society of Hematology.
Conflict of interest statement
Conflict-of-interest disclosure: R.S., C.D.L., K.A., and T.K. are or were employees of Novo Nordisk A/S during the study. C.D.L., K.A., and T.K. are minor shareholders of Novo Nordisk A/S. At the University of Copenhagen, L.H.O. was affiliated with the in vivo pharmacology research center LIFEPHARM, which was supported by Novo Nordisk A/S. M.J.F. has previously received research funding from Novo Nordisk A/S, but in a research area separate and distinct from the plasminogen and hemophilia A studies reported in the present manuscript.
Figures





Similar articles
-
Characterization of a genetically engineered mouse model of hemophilia A with complete deletion of the F8 gene.J Thromb Haemost. 2016 Feb;14(2):346-55. doi: 10.1111/jth.13202. Epub 2016 Jan 8. J Thromb Haemost. 2016. PMID: 26588198 Free PMC article.
-
Abrogating fibrinolysis does not improve bleeding or rFVIIa/rFVIII treatment in a non-mucosal venous injury model in haemophilic rodents.J Thromb Haemost. 2018 Jul;16(7):1369-1382. doi: 10.1111/jth.14148. Epub 2018 Jun 21. J Thromb Haemost. 2018. PMID: 29758126 Free PMC article.
-
Preclinical pharmacokinetics and biodistribution of subcutaneously administered glycoPEGylated recombinant factor VIII (N8-GP) and development of a human pharmacokinetic prediction model.J Thromb Haemost. 2018 Jun;16(6):1141-1152. doi: 10.1111/jth.14013. Epub 2018 May 10. J Thromb Haemost. 2018. PMID: 29582559
-
The evolving understanding of factor VIII binding sites and implications for the treatment of hemophilia A.Blood Rev. 2019 Jan;33:1-5. doi: 10.1016/j.blre.2018.05.001. Epub 2018 May 24. Blood Rev. 2019. PMID: 29866493 Review.
-
Turoctocog alfa for the treatment of hemophilia A.Drugs Today (Barc). 2014 Feb;50(2):121-31. doi: 10.1358/dot.2014.50.2.2116671. Drugs Today (Barc). 2014. PMID: 24619589 Review.
Cited by
-
Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A.Sci Transl Med. 2024 Feb 21;16(735):eadh0027. doi: 10.1126/scitranslmed.adh0027. Epub 2024 Feb 21. Sci Transl Med. 2024. PMID: 38381848 Free PMC article.
-
Hypofibrinogenemia with preserved hemostasis and protection from thrombosis in mice with an Fga truncation mutation.Blood. 2022 Mar 3;139(9):1374-1388. doi: 10.1182/blood.2021012537. Blood. 2022. PMID: 34905618 Free PMC article.
-
Plasminogen Deficiency and Amiloride Mitigate Angiotensin II-Induced Hypertension in Type 1 Diabetic Mice Suggesting Effects Through the Epithelial Sodium Channel.J Am Heart Assoc. 2020 Dec;9(23):e016387. doi: 10.1161/JAHA.120.016387. Epub 2020 Nov 20. J Am Heart Assoc. 2020. PMID: 33215566 Free PMC article.
-
Sustained depletion of FXIII-A by inducing acquired FXIII-B deficiency.Blood. 2020 Dec 17;136(25):2946-2954. doi: 10.1182/blood.2020004976. Blood. 2020. PMID: 32678423 Free PMC article.
-
Bleeding is increased in amyloid precursor protein knockout mouse.Res Pract Thromb Haemost. 2020 Jun 14;4(5):823-828. doi: 10.1002/rth2.12375. eCollection 2020 Jul. Res Pract Thromb Haemost. 2020. PMID: 32685890 Free PMC article.
References
-
- Carmeliet P, Schoonjans L, Kieckens L, et al. . Physiological consequences of loss of plasminogen activator gene function in mice. Nature. 1994;368(6470):419-424. - PubMed
-
- Schuster V, Hügle B, Tefs K. Plasminogen deficiency. J Thromb Haemost. 2007;5(12):2315-2322. - PubMed
-
- Tefs K, Gueorguieva M, Klammt J, et al. . Molecular and clinical spectrum of type I plasminogen deficiency: a series of 50 patients. Blood. 2006;108(9):3021-3026. - PubMed
-
- Mehta R, Shapiro AD. Plasminogen deficiency. Haemophilia. 2008;14(6):1261-1268. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous